Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies

Kurosawa, Mitsutoshi; Yonezumi, Masakatsu; Hashino, Satoshi; Tanaka, Junji; Nishio, Mitsufumi; Kaneda, Makoto; Ota, Shuichi; Koda, Kyuhei; Suzuki, Nobuhiro; Yoshida, Makoto; Hirayama, Yasuo; Takimoto, Rishu; Torimoto, Yoshihiro; Mori, Akio; Takahashi, Tohru; Iizuka, Susumu; Ishida, Tadao; Kobayashi, Ryōji; Oda, Takanori; Sakai, Hajime; Yamamoto, Satoshi; Takahashi, Fumihiko; Fukuhara, Takashi

doi:10.1007/s12185-012-1210-y

Cited by 110 publications

(91 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…was the most common causative agent in probable/proven IFI, supporting the previously reported data (17). The incidence of aspergillosis was 5.9%, which was slightly higher than that declared in other studies (0.8%-2.6%) (6,7,15). The environmental conditions of our clinic might have led to increased IFI rates, as longterm refurbishment studies might have exacerbated moldrelated fungal infections.…”

Section: Discussionsupporting

confidence: 89%

Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience

Soyer¹,

Ünal²,

Vural³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Invasive fungal infection (IFI) causes morbidity and mortality among patients with hematological malignancies. We evaluated the incidence and treatment characteristics of IFIs between October 2012 and December 2013. Materials and methods:Patients who received chemotherapy or stem cell transplantation were retrospectively evaluated. Fungal infections were classified according to EORTC criteria.Results: Prophylaxis and antifungal therapy were given in 30.5% and 23.6% of 522 chemotherapy courses, respectively. The incidence of proven/probable IFI was 6.7%. The incidence of IFI among patients who received prophylaxis was significantly higher than among those who did not receive it (11.3% vs. 4.6%, P = 0.005). There was no significant difference between patients who received mold-active and no mold-active prophylaxis (P = 0.098). The most common single agent therapy and causative pathogen was liposomal amphotericin B (57.1%) and Aspergillus (n = 5), respectively. IFI-attributable mortality rate was 14.2% in 6 weeks. Conclusion:The IFI incidence and mortality rate were similar to that reported in the literature. The IFI rate was higher in the group using prophylaxis, as this is a high-risk group. Although the IFI rate was not significantly different between groups using prophylaxis, patients should be followed closely for the effective use of posaconazole prophylaxis.

show abstract

Section: Discussionsupporting

confidence: 89%

Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience

Soyer¹,

Ünal²,

Vural³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Впоследниегодыотмеченростчисламикотиче-ских заболеваний у онкогематологических больных на фоне тяжелой нейтропении и/или проводимой иммуносупрессивнойтерапии [5,6].Этосвязаноссо-вершенствованием методов диагностики микозов, атакжесболее«агрессивными»схемамицитостати-ческойтерапии,широкимиспользованиемтрансплан-тациигемопоэтическихстволовыхклетоккак«терапии спасения».Известно,чтоуонкогематологическихболь-ныхосновнымиИМявляютсяИАимукормикоз [6][7][8].…”

Section: Discussionunclassified

Invasive Aspergillosis and Mucormycosis in Oncohematological Patients

et al. 2018

View full text Add to dashboard Cite

Russia; 6-8 L'va Tolstogo St., 197022 Saint Petersburg, Russia; 4 Leningrad Regional Clinical Hospital; 45-49 Lunacharskogo Prospect, 197022 Saint Petersburg, Russia In the retrospective multicenter study during [2007][2008][2009][2010][2011][2012][2013][2014][2015][2016][2017] we included 59 oncohematological patients with mucormycosis and 541 patients with invasive aspergillosis. Our study showed that mucomorhycosis more often developed in children and adolescents (p = 0.001), and after «graft versus host» disease development (p = 0.0001). Patients with mucormycosis were more immunosuppressed: severe neutropenia was in 88 % vs. 82 %, median duration of neutropenia -30 days vs. 14 days, p = 0.0001, lymphocytopenia -77 % vs. 65 %, median duration of lymphocytopenia -25 days vs. 14 days, p = 0.001. The main sites of infection were lungs, nevertheless in patients with mucormycosis it was less frequent (73 % vs. 97 %, p = 0.02), but more frequent were ≥2 organs involvement (42 % vs. 8 %, p = 0.001) and paranasal sinuses involvement (15 % vs. 6 %, p = 0.04

show abstract

“…Roden MM et al reported infection sites of mucormycosis in patients with malignancy. Respiratory accounts for the majority (60 %), gastrointestinal accounts for only 3 % [3]. Thus, in patients with malignancy, gastrointestinal mucormycosis is rare.…”

Section: American Journal Of Infectious Diseases and Microbiologymentioning

confidence: 99%

Large Intestine Infarction due to Mucormycosis Complicated with Acute Myeloid Leukemia. Case Report

Shibusawa¹,

Hidai²,

Motomura³

et al. 2014

AJIDM

View full text Add to dashboard Cite

Mucormycosis is known to be fatal, and the diagnosis is difficult to be made. Gastrointestinal mucormycosis is rarely complicated with gastrointestinal infarction. We report a rare case of mucormycosis complicated with large intestine infarction. An 82-year-old man was admitted to our hospital, because of blastosis. A diagnosis of acute myeloid leukemia prior myelodysplastic syndrome was made. On the twentieth day of admission, bleeding developed in the airway secondary to thrombocytopenia and disseminated intravascular coagulation. He died due to respiratory failure and autopsy was carried out. The novel finding of the autopsy was large intestine infarction due to mucormycosis, although the clinical course did not show features suggesting gastrointestinal mucormycosis. A diagnosis of mucormycosis was made by autopsy. In the patients with risk factors including hematologic malignancies, we should pay attention to gastrointestinal mucormycosis.

show abstract

Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies

Cited by 110 publications

References 34 publications

Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience

Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience

Invasive Aspergillosis and Mucormycosis in Oncohematological Patients

Large Intestine Infarction due to Mucormycosis Complicated with Acute Myeloid Leukemia. Case Report

Contact Info

Product

Resources

About